In a recent study published in the journal Nature Medicine, researchers examine clinical glioblastoma and benign intracranial samples to determine the presence and function of immune cells in the ...

AC Immune (ACIU) to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

To date, no clinically relevant safety issues have been reported other than transient injection site reactions (49%) and headaches (18%). Patients from Part 2 will be evaluated for the progression of ...

Although there has been a rush for things to return “normal,” the truth is that living with Covid is our new reality. The Root talked to the esteemed Dr. Melissa Clarke about ways we can build ...

− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to ...

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations 100% of patients receiving ACI-7104.056 responded ...

Figure 1. CANscript™ is a multidimensional live-tissue platform that recreates the patient’s unique tumor microenvironment ex vivo. It can personalize patient care by predicting how individual ...

AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. Click to read why ACIU is a Buy.

CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after ...

Your immune system is supposed to fight diseases and help your body recover. But in some cases, it may be weak, less active than necessary, overactive, or it may even attack ...

OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license ...